Search Results for "R"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for R. Results 951 to 960 of 1000 total matches.

Prevention and Treatment of Injury from Chemical Warfare Agents

   
The Medical Letter on Drugs and Therapeutics • Jan 07, 2002  (Issue 1121)
., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS ...
The recent terrorist attacks on the US have led to many questions about the clinical effects, prevention and treatment of injury caused by chemical warfare agents.
Med Lett Drugs Ther. 2002 Jan 7;44(1121):1-4 |  Show IntroductionHide Introduction

Safety of Aggressive Statin Therapy

   
The Medical Letter on Drugs and Therapeutics • Nov 22, 2004  (Issue 1196)
of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New York ...
New guidelines from The National Cholesterol Education Program recommend, as a therapeutic option, lowering treatment goals for LDL cholesterol (LDL-C) from <100 mg/dL to <70 mg/dL for patients at very high risk for coronary heart disease and from 130 mg/dL to <100 mg/dL for those at moderately high risk. A likely consequence of these recommendations is increased use of statins and use of higher doses with a concomitant increase in adverse effects.
Med Lett Drugs Ther. 2004 Nov 22;46(1196):93-5 |  Show IntroductionHide Introduction

Treatment of Menopausal Vasomotor Symptoms

   
The Medical Letter on Drugs and Therapeutics • Dec 06, 2004  (Issue 1197)
, Copenhagen Dan M. Roden, M.D., Vanderbilt School of Medicine F. Estelle R. Simons, M.D., University ...
Estrogen is the most effective treatment for menopausal vasomotor symptoms (hot flashes), but the Women's Health Initiative study found that women who took estrogen plus a progestin for more than 5 years were at increased risk for myocardial infarction, stroke, pulmonary emboli, deep vein thrombosis, breast cancer, and possibly dementia. Are there effective alternatives?
Med Lett Drugs Ther. 2004 Dec 6;46(1197):98-9 |  Show IntroductionHide Introduction

Antiplatelet Therapy for Patients with Stents

   
The Medical Letter on Drugs and Therapeutics • Aug 11, 2008  (Issue 1292)
. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University ...
The antiplatelet agents aspirin and clopidogrel (Plavix, and others) are used in most patients undergoing percutaneous coronary intervention (PCI) to prevent stent thrombosis and to reduce the occurrence of peri-, post-procedural and late cardiovascular events. Despite a large number of randomized trials of these agents in such patients, the optimal dosage and duration of treatment with these drugs, and whether other drugs should be added, is unclear.
Med Lett Drugs Ther. 2008 Aug 11;50(1292):61-3 |  Show IntroductionHide Introduction

Saxagliptin (Onglyza) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Nov 02, 2009  (Issue 1324)
Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine F. Estelle R. Simons, M.D., University ...
Saxagliptin (Onglyza - Bristol-Myers Squibb), the second oral dipeptidyl peptidase-4 (DPP-4) inhibitor to be marketed in the US, has been approved by the FDA for treatment of adults with type 2 diabetes.
Med Lett Drugs Ther. 2009 Nov 2;51(1324):85-6 |  Show IntroductionHide Introduction

Two New Intra-Articular Injections for Knee Osteoarthritis

   
The Medical Letter on Drugs and Therapeutics • Aug 27, 2018  (Issue 1554)
; 30:279. 5. R Leighton et al. NASHA hyaluronic acid vs. methylprednisolone for knee osteoarthritis ...
The FDA has approved a single-injection hyaluronic acid gel (Durolane – Bioventus) and an extended-release (ER) formulation of the synthetic corticosteroid triamcinolone acetonide (Zilretta – Flexion) for intra-articular (IA) treatment of osteoarthritic knee pain.
Med Lett Drugs Ther. 2018 Aug 27;60(1554):142-4 |  Show IntroductionHide Introduction

Booster Doses of COVID-19 Vaccines

   
The Medical Letter on Drugs and Therapeutics • Nov 29, 2021  (Issue 1638)
at: https://bit.ly/3EdYPVk. Accessed October 29, 2021. 11. R Zhang and T Brennan. FDA review ...
The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) and the adenovirus-based vaccine manufactured by Johnson & Johnson/Janssen to include administration of a booster dose in select populations after primary immunization with either the same COVID-19 vaccine or a different one.
Med Lett Drugs Ther. 2021 Nov 29;63(1638):186-8 |  Show IntroductionHide Introduction

Drugs for Head Lice

   
The Medical Letter on Drugs and Therapeutics • Jun 10, 2024  (Issue 1704)
Vamousse AirAlle LouseBuster lindane Ovide malathion pyrethrins R&C Rid permethrin Nix Elimite ivermectin ...
Pediculosis capitis (head lice infestations) occur in all age groups, but especially in elementary school children. In most cases, transmission occurs by head-to-head contact. Pharmacologic treatment is recommended for persons with live lice or eggs (nits) within 1 cm of the scalp. Topical pediculicides should be tried first. Oral therapy is occasionally required for refractory infestations.
Med Lett Drugs Ther. 2024 Jun 10;66(1704):89-92   doi:10.58347/tml.2024.1704a |  Show IntroductionHide Introduction

Drugs for Atopic Dermatitis

   
The Medical Letter on Drugs and Therapeutics • Jun 15, 2020  (Issue 1600)
IV open-label study (CrisADe CARE 1). Am J Clin Dermatol 2020; 21:275. 15. R Sidbury et al ...
Atopic dermatitis (AD; also known as eczema) is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and has a relapsing course, often improving by adolescence, but sometimes persisting into (or first appearing in) adulthood or even old age.
Med Lett Drugs Ther. 2020 Jun 15;62(1600):89-96 |  Show IntroductionHide Introduction

Drugs for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021  (Issue 1637)
. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014; 370:2377. 22. R Fleischmann et ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were recently updated. The goal of treatment is to minimize disease activity and prevent irreversible joint damage.
Med Lett Drugs Ther. 2021 Nov 15;63(1637):177-84 |  Show IntroductionHide Introduction